Clinical relevance of increased neuron-specific enolase concentration in cerebrospinal fluid.
Neuron-specific enolase (NSE) concentrations in cerebrospinal fluid (CSF) and serum have been studied by an EIA-method using monoclonal antibodies against human NSE. In a control group (n = 24) the mean NSE value (+/- SD) in CSF was 10.8 (+/- 4.5) ng/ml. Increased NSE values in CSF (greater than or equal to 20 ng/ml, ie greater than or equal to means + 2s) have been detected in 33/172 patients with the following neurological diseases: CNS tumors (6/30), infarctions (6/36), cerebral ischemias (5/25), inflammatory diseases (7/33), epilepsias (3/10) and miscellaneous neurological diseases (6/38). The NSE assay in CSF was not specific for a single neurological disease. In 9% of all patients with an organic neurological disease the increased NSE concentration was the only abnormal result in the CNS out of variables routinely determined in CSF. The discrimination between an organic and psychogenic origin of epilepsy may be possible by an NSE analysis in CSF. The NSE assay in CSF can be recommended as an unspecific screening parameter for pathological organic CNS processes.
D000911:Antibodies, Monoclonal; D015415:Biomarkers; D001932:Brain Neoplasms / Q000134:cerebrospinal fluid / Q000201:enzymology; D002493:Central Nervous System Diseases / Q000134:cerebrospinal fluid / Q000201:enzymology; D002561:Cerebrovascular Disorders / Q000134:cerebrospinal fluid / Q000201:enzymology; D004827:Epilepsy / Q000134:cerebrospinal fluid / Q000201:enzymology; D006801:Humans; D007124:Immunoenzyme Techniques; D009422:Nervous System Diseases / Q000134:cerebrospinal fluid / Q000201:enzymology*; D010751:Phosphopyruvate Hydratase / Q000097:blood / Q000134:cerebrospinal fluid*
D000911:Antibodies, Monoclonal; D015415:Biomarkers; D010751:Phosphopyruvate Hydratase